摘要
目的探讨氟尿嘧啶植入剂在Ⅲ期胃癌患者根治术中应用的临床疗效。方法分析中山市人民医院1999年1月至2002年12月收治的200例Ⅲ期胃癌根治术患者（120例患者术中使用氟尿嘧啶植入剂）的一般情况及生存情况，观察氟尿嘧啶植入剂在胃癌患者根治术中应用的临床疗效。结果两组在体重（P=0．041）、血红蛋白（P=0．024）、血小板（P=0．017）及肿瘤标志物CEA（P=0．001）、CA199（P=0．003）之间差异有统计学意义。治疗组恶心、呕吐的发生率（28％）高于对照组（17％，P=0．006）；两组骨髓抑制（P=0．81）、腹泻（P=0．72）、肝功能损害（P=0．97）及肾功能损害（P=0．20）的发生率差异无统计学意义。5年累积生存率治疗组（45％）高于对照组（15％，P=0．002）。结论胃癌根治术中应用氟尿嘧啶植入剂可显著提高患者的临床疗效。
Objective To investigate the therapeutic effects offluorouracil implants in Stage Ⅲgastric carcinoma patients after radical gastrectomy. Methods The general state of health and cumulative survival of 200 stage Ⅲ gastric carcinoma patients undergone radical gastrectomy from January, 1999 to, December 2002 in the People＇ s Hospital of Zhongshan City were analyzed, in which only 120 patients administrated fluorouracil implants during radical gastrectomy. The therapeutic effects of fluorouracil implants in stage Ⅲ gastric carcinoma patients after radical gastrectomy were observed. Results The differences of weight （P = 0.041）, HGB（P =0.024）, Plt（P =0.017）, CEA （P =0.001）, CA19-9（P =0.003） were significant between two groups. The incidence rate of nausea/emesis in group T （28 %） was higher than that in group 0（17 %, P = 0.006）, and incidence rates of myelosuppression（P =0.81）, diarrhea（P =0.72）, hepatic function lesion（P =0.97） and renal function lesion（P =0.20） were no significant. The cumulative 5-year survival rate of group T（45 %） was higher than that in group 0 （15 %, P =0.002）. Conclusion Fluorouracil implants can improve the therapeutic effects on gastric carcinoma patients undergone radical gastrectomy.
出处
《肿瘤研究与临床》
CAS
2009年第5期338-340,共3页
Cancer Research and Clinic
关键词
药物植入物
胃肿瘤
外科手术
Drug implants
Stomach neoplasms
Surgical procedures operation
